Yaz And Yasmin Promoted For Unapproved Off-label Use According To Bayer Documents
Company e-mails of Bayer AG, which is the largest drug manufacturer in Germany, appear to indicate that they wished to promote their birth control drug Yaz for unapproved off-label uses and mislead women about the drug's safety. (Here is a previous post providing a summary of the Yaz problems and litigation.)
Just last month the FDA released a report of a study concluding that women experience a 74% increase in developing blood clots compared to women on other birth control drugs.The documents turned over in the ongoing lawsuits over the drugs' side effects appear to demonstrate that Bayer knew of the blood clot risks, but withheld the information from regulators, doctors and patients.
Another set of e-mails seem to indicate that Bayer wanted to promote Yaz for purposes for which it was not approved. The e-mail from a sales consultant to sales representatives appears to be targeted to enlarge the uses of Yaz among doctors.
I am familiar with this litigation as I have filed suits on behalf of clients against the drug manufacturers. The first trials in the litigation are set for January 2012.
Dangerous and defective drugs are responsible for many injuries and death nationwide. Our profession calls this area of law products liability. Consulting a lawyer experienced in handling these matters is usually easy. Most lawyers will provide a complimentary initial consultation to evaluate a claim or case and let the person know if they can help.